Marie-Helene Saint-Hilaire

Marie-Helene Saint-Hilaire

Auto-generated profile, based on publicly available information

Marie-Helene Saint-Hilaire

Boston University School of Medicine Roxbury MA United States

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2012 in Neurology
Verified
Journal Article
Closed access
PDF file
JLJ.-M. Lee
J.-M. Lee
ERE.M. Ramos
E.M. Ramos
JLJ.-H. Lee
J.-H. Lee
TGT. Gillis
T. Gillis
JMJ.S. Mysore
J.S. Mysore
JGJ.F. Gusella
J.F. Gusella
Objective: Age at onset of diagnostic motor manifestations in Huntington disease (HD) is strongly correlated with an expanded CAG trinucleotide repeat. The length of the normal CAG repeat allele has been reported also to influence age at onset, in interaction with the expanded allele. Due to profound implications for disease mechanism and modification, we tested whether the normal allele, interaction between the expanded and normal alleles, or presence of a second expanded allele affects age at onset of HD motor signs. Methods: We modeled natural log-transformed age at onset as a function of CAG repeat lengths of expanded and normal alleles and their interaction by linear regression. Results: An apparently significant effect of interaction on age at motor onset among 4,068 subjects was dependent on a single outlier data point. A rigorous statistical analysis with a well-behaved dataset that conformed to the fundamental assumptions of linear regression (e.g., constant variance and normally distributed error) revealed significance only for the expanded CAG repeat, with no effect of the normal CAG repeat. Ten subjects with 2 expanded alleles showed an age at motor onset consistent with the length of the larger expanded allele. Conclusions: Normal allele CAG length, interaction between expanded and normal alleles, and presence of a second expanded allele do not influence age at onset of motor manifestations, indicating that the rate of HD pathogenesis leading to motor diagnosis is determined by a completely dominant action of the longest expanded allele and as yet unidentified genetic or environmental factors. Neurology® 2012;78:690–695

1 September 1987 in Neurology
Verified
Journal Article
Closed access
PDF file
ABA.-M. Bonnet
A.-M. Bonnet
YLY. Loria
Y. Loria
MSM.-H. Saint-Hilaire
M.-H. Saint-Hilaire
FLF. Lhermitte
F. Lhermitte
YAY. Agid
Y. Agid
The motor score with and without levodopa was estimated in 193 parkinsonian patients with variable length of evolution. The effect of levodopa on akinesia, rigidity, and tremor remained quite stable during the course of the disease. In contrast, the aggravation of gait disorder, postural instability, and dysarthria was more severe, with decreased percentage of improvement on levodopa in patients with longer evolution. It is suggested that aggravation of Parkinson9s disease mainly results from increasing severity of cerebral nondopaminergic lesions.

1 November 2010 in Environmental Health Perspectives
Verified
Journal Article
Open access
MWMarc G. Weisskopf
Marc G. Weisskopf
JWJennifer Weuve
Jennifer Weuve
HNHuiling Nie
Huiling Nie
MSMarie-Helene Saint-Hilaire
Marie-Helene Saint-Hilaire
LSLewis Sudarsky
Lewis Sudarsky
HHHoward Hu
Howard Hu
A peer-reviewed open access journal published by the National Institute of Environmental Health Sciences

1 October 1997 in Neurology
Verified
Journal Article
Closed access
PDF file
ARA. H. Rajput
A. H. Rajput
WMW. Martin
W. Martin
MSM. H. Saint-Hilaire
M. H. Saint-Hilaire
EDE. Dorflinger
E. Dorflinger
SPS. Pedder
S. Pedder
We studied the new catechol-O-methyltransferase inhibitor tolcapone, 100 and 200 mg, three times daily (tid) in a randomized, double-blind, parallel-group trial involving 202 parkinsonian patients who were experiencing the "wearing-off" phenomenon on levodopa therapy. After 3 months, patients receiving tolcapone had a significant decrease in mean daily levodopa dose requirement compared with placebo-treated patients (p< 0.01). In patients treated with tolcapone 200 mg tid, daily "off" time, measured using patient diaries, was reduced from baseline by 3.25 hours; this reduction was significantly different from that seen in the placebo group(p < 0.01). Moreover, the number of daily levodopa intakes was reduced significantly in each tolcapone group compared with placebo(p < 0.01). We found significant improvements in motor function and overall efficacy in the tolcapone groups (p < 0.01). The most frequent adverse events were associated with levodopa treatment. Dyskinesia developed or worsened in 18% of patients receiving placebo, in 51% receiving tolcapone 100 mg tid, and in 64% receiving 200 mg tid, with most cases occurring within the first 30 days of the study. Diarrhea was the most frequent nondopaminergic event, occurring in 14% on placebo, 13% on tolcapone 100 mg tid, and 19% on 200 mg tid. Overall 18% of patients withdrew because of adverse events: 15% on placebo, 17% on tolcapone 100 mg tid, and 22% on 200 mg tid. We conclude that tolcapone as an adjunct offers promise for the relief of the "wearing-off" phenomenon in levodopa-treated parkinsonian patients.

30 January 2010 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
LTLinda Tickle-Degnen
Linda Tickle-Degnen
TETerry Ellis
Terry Ellis
MSMarie H. Saint‐Hilaire
Marie H. Saint‐Hilaire
CTCathi A. Thomas
Cathi A. Thomas
RWRobert C. Wagenaar
Robert C. Wagenaar

1 September 2003 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JLJian-Liang Li
Jian-Liang Li
MHMichael R. Hayden
Michael R. Hayden
EAElisabeth W. Almqvist
Elisabeth W. Almqvist
RBRyan R. Brinkman
Ryan R. Brinkman
ADAlexandra Durr
Alexandra Durr
RMRichard H. Myers
Richard H. Myers